# Eli Lilly's GLP-1 Pill Foundayo Shows Efficacy for Sleep Apnea Treatment New clinical trials indicate Foundayo reduces sleep apnea severity and improves cardiovascular health markers. - **Source:** [Time](https://time.com) - **Published:** 2026-11-09 - **Topic:** [health](https://brifing.si/c/health) - **Original article:** - **On Brifing:** https://brifing.si/s/6232d139-5007-4d24-b301-39067cd662a7 ## Expanding GLP-1 Therapeutic Scope Researchers are exploring benefits of GLP-1 medications beyond diabetes and weight management. Eli Lilly’s oral drug Foundayo, known as orforglipron, recently demonstrated success in reducing obstructive sleep apnea episodes. Clinical data suggests these treatments may address obesity-related conditions by targeting hormones, potentially offering patients alternatives to traditional injectable therapies. ## Sleep Apnea Clinical Findings A study involving over 700 participants across nine countries evaluated Foundayo’s impact on moderate-to-severe sleep apnea. After 52 weeks, patients experienced a significant reduction in breathing interruptions. Specifically, those not using positive airway pressure machines saw a 43.8% decrease in symptom severity, while PAP users saw a 27.5% reduction. ## Weight Loss and Mechanism Participants in the clinical trial lost an average of 28 pounds, representing approximately 11% of their starting body weight. Weight reduction is a primary factor in alleviating sleep apnea, as excess tissue can restrict airways. Foundayo functions as a daily pill, distinguishing it from existing weekly injectable GLP-1 options. ## Cardiovascular and Inflammatory Impact Beyond respiratory improvements, Foundayo users showed lower blood pressure and reduced levels of CRP, a key inflammatory marker. Obstructive sleep apnea causes oxygen deprivation, which strains the heart and increases stroke risk. By mitigating these episodes, the drug may provide secondary cardiovascular health benefits for overweight or obese patients. ## Future Regulatory Approval Plans Eli Lilly intends to submit a formal request to the FDA by the end of 2026 for Foundayo’s approval to treat obstructive sleep apnea. Currently, the drug is approved for chronic weight management. If successful, it would become the third Lilly product indicated for managing this specific sleep-related breathing disorder. ## Retatrutide and Knee Pain In separate research, the experimental injectable retatrutide showed promise for osteoarthritis in the knee. Targeting three weight-related hormones, the drug helped two-thirds of participants report a 50% reduction in pain. Researchers suggest this relief stems from both reduced joint load and potential anti-inflammatory effects inherent to GLP-1 compounds. ## Metabolic and Physical Relief Osteoarthritis pain involves complex mechanisms, including physical joint stress and metabolic factors from fat cells. While weight loss directly reduces mechanical pressure on knees, the anti-inflammatory properties of GLP-1 drugs may also play a role. Lilly is currently expanding its research to investigate retatrutide’s efficacy for chronic low back pain. ## Clinical Implications and Outlook These findings highlight a shift toward using GLP-1 therapies for systemic obesity-related comorbidities. By addressing both respiratory and joint health, these drugs represent a broader approach to metabolic medicine. Future studies will continue to monitor long-term cardiovascular safety and the specific mechanisms driving these diverse therapeutic outcomes in patients. ## Sources covering this story - [Scientific American — Eli Lilly's GLP-1 Pill Foundayo Shows Promise for Sleep Apnea](https://www.scientificamerican.com/article/eli-lilly-shows-glp-1-weight-loss-pill-foundayo-can-dramatically-improve-sleep-apnea/) - [Time — GLP-1 Drugs Show Promise for Sleep Apnea and Arthritis Relief](https://time.com/article/2026/11/09/glp-1-weight-loss-drugs-may-help-sleep-apnea-and-arthritis/) - [Scientific American Content: Global — Eli Lilly's GLP-1 Pill Foundayo Shows Efficacy Against Sleep Apnea](https://www.scientificamerican.com/article/eli-lilly-shows-glp-1-weight-loss-pill-foundayo-can-dramatically-improve-sleep-apnea/) - [TIME — GLP-1 Drugs Show Promise for Sleep Apnea and Arthritis Relief](https://time.com/article/2026/11/09/glp-1-weight-loss-drugs-may-help-sleep-apnea-and-arthritis/) - [TIME — GLP-1 Drugs Show Promise for Sleep Apnea and Arthritis Relief](https://time.com/article/2026/11/09/glp-1-weight-loss-drugs-may-help-sleep-apnea-and-arthritis/) --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._